Investigating the effect of citalopram with haloperidol in the treatment of delirium in intensive care patients

Phase 3

Recruiting

• Conditions: delirium.; Delirium due to known physiological condition

• Registration Number: IRCT20191104045328N18
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 146

Inclusion Criteria

All patients diagnosed with delirium by DSM5 criteria.
Age over 18 years to 80 years
RASS criterion greater than or equal to 3
Patients should not be in a coma for more than 24 hours and do not have a structural reason for their low level of consciousness

Exclusion Criteria

Pregnancy and breastfeeding
Hypersensitivity to citalopram and haloperidol
presence of QTC more than 440 milliseconds
Having a history of taking SSRIs
The presence of primary neurological disease such as stroke, dementia, psychosis
Very severe cataract
Presence of malignancy and severe sepsis
Presence of severe metabolic disorders such as DKA and hyperosmolar coma
Presence of mental disorder or disability before hospitalization
Unstable vital signs
Having a history of drug-requiring seizures, cardiovascular and liver disease, myasthenia gravis and thyrotoxicosis
Poisoning by an unknown drug
Bone marrow suppression

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sedation. Timepoint: Before the intervention, the first day to the seventh days. Method of measurement: Richmond Agitation Sedation Scale (RASS).;Illness severity. Timepoint: Before the intervention, the first day to the seventh days. Method of measurement: APACHE II Score.